| Rank |
Title |
Journal |
Year |
PubWeight™‹?› |
|
1
|
A protective and broadly cross-neutralizing epitope of human papillomavirus L2.
|
J Virol
|
2007
|
2.36
|
|
2
|
Cross-neutralization of cutaneous and mucosal Papillomavirus types with anti-sera to the amino terminus of L2.
|
Virology
|
2005
|
2.31
|
|
3
|
Further evidence that papillomavirus capsids exist in two distinct conformations.
|
J Virol
|
2003
|
2.02
|
|
4
|
Crystal structures of four types of human papillomavirus L1 capsid proteins: understanding the specificity of neutralizing monoclonal antibodies.
|
J Biol Chem
|
2007
|
1.77
|
|
5
|
Human papillomaviruses bind a basal extracellular matrix component secreted by keratinocytes which is distinct from a membrane-associated receptor.
|
Virology
|
2005
|
1.73
|
|
6
|
Protection of rabbits against challenge with rabbit papillomaviruses by immunization with the N terminus of human papillomavirus type 16 minor capsid antigen L2.
|
J Virol
|
2007
|
1.70
|
|
7
|
Keratinocyte-secreted laminin 5 can function as a transient receptor for human papillomaviruses by binding virions and transferring them to adjacent cells.
|
J Virol
|
2006
|
1.67
|
|
8
|
Protective immunity to rabbit oral and cutaneous papillomaviruses by immunization with short peptides of L2, the minor capsid protein.
|
J Virol
|
2002
|
1.48
|
|
9
|
Type-specific antiviral antibodies to genital human papillomavirus types in mothers and newborns.
|
Reprod Sci
|
2007
|
1.43
|
|
10
|
IL-13Ralpha2 is a glioma-restricted receptor for interleukin-13.
|
Neoplasia
|
2002
|
1.42
|
|
11
|
Kinetics of in vitro adsorption and entry of papillomavirus virions.
|
Virology
|
2004
|
1.37
|
|
12
|
Identification of two cross-neutralizing linear epitopes within the L1 major capsid protein of human papillomaviruses.
|
J Virol
|
2002
|
1.35
|
|
13
|
Reactivity pattern of 92 monoclonal antibodies with 15 human papillomavirus types.
|
J Gen Virol
|
2008
|
1.35
|
|
14
|
Propagation, infection, and neutralization of authentic HPV16 virus.
|
Virology
|
2004
|
1.32
|
|
15
|
Identification of a human papillomavirus type 16-specific epitope on the C-terminal arm of the major capsid protein L1.
|
J Virol
|
2003
|
1.27
|
|
16
|
A papillomavirus-like particle (VLP) vaccine displaying HPV16 L2 epitopes induces cross-neutralizing antibodies to HPV11.
|
Vaccine
|
2006
|
1.25
|
|
17
|
A small molecule antagonist of the alpha(v)beta3 integrin suppresses MDA-MB-435 skeletal metastasis.
|
Clin Exp Metastasis
|
2004
|
1.23
|
|
18
|
Quantitative RT-PCR assay for HPV infection in cultured cells.
|
J Virol Methods
|
2003
|
1.23
|
|
19
|
The viral E4 protein is required for the completion of the cottontail rabbit papillomavirus productive cycle in vivo.
|
J Virol
|
2004
|
1.18
|
|
20
|
Tissue-spanning redox gradient-dependent assembly of native human papillomavirus type 16 virions.
|
J Virol
|
2009
|
1.18
|
|
21
|
Intracutaneous DNA vaccination with the E8 gene of cottontail rabbit papillomavirus induces protective immunity against virus challenge in rabbits.
|
J Virol
|
2002
|
1.15
|
|
22
|
Chimeric human papillomavirus type 16 (HPV-16) L1 particles presenting the common neutralizing epitope for the L2 minor capsid protein of HPV-6 and HPV-16.
|
J Virol
|
2003
|
1.11
|
|
23
|
Wounding prior to challenge substantially improves infectivity of cottontail rabbit papillomavirus and allows for standardization of infection.
|
J Virol Methods
|
2007
|
1.11
|
|
24
|
Impact of genetic changes to the CRPV genome and their application to the study of pathogenesis in vivo.
|
Virology
|
2006
|
1.10
|
|
25
|
Protection of rabbits against cutaneous papillomavirus infection using recombinant tobacco mosaic virus containing L2 capsid epitopes.
|
Vaccine
|
2006
|
1.10
|
|
26
|
An HLA-A2.1-transgenic rabbit model to study immunity to papillomavirus infection.
|
J Immunol
|
2006
|
1.09
|
|
27
|
Preclinical model to test human papillomavirus virus (HPV) capsid vaccines in vivo using infectious HPV/cottontail rabbit papillomavirus chimeric papillomavirus particles.
|
J Virol
|
2006
|
1.08
|
|
28
|
Papillomavirus particles assembled in 293TT cells are infectious in vivo.
|
J Virol
|
2006
|
1.08
|
|
29
|
Binding and neutralization efficiencies of monoclonal antibodies, Fab fragments, and scFv specific for L1 epitopes on the capsid of infectious HPV particles.
|
Virology
|
2007
|
1.07
|
|
30
|
A novel HLA (HLA-A*0201) transgenic rabbit model for preclinical evaluation of human CD8+ T cell epitope-based vaccines against ocular herpes.
|
J Immunol
|
2010
|
1.06
|
|
31
|
Amino acid residues in the carboxy-terminal region of cottontail rabbit papillomavirus E6 influence spontaneous regression of cutaneous papillomas.
|
J Virol
|
2002
|
1.05
|
|
32
|
Overlapping and independent structural roles for human papillomavirus type 16 L2 conserved cysteines.
|
Virology
|
2009
|
1.01
|
|
33
|
Large cutaneous rabbit papillomas that persist during cyclosporin A treatment can regress spontaneously after cessation of immunosuppression.
|
J Gen Virol
|
2005
|
0.98
|
|
34
|
Differential antibody responses to a distinct region of human papillomavirus minor capsid proteins.
|
Vaccine
|
2004
|
0.98
|
|
35
|
In vivo programming of tumor antigen-specific T lymphocytes from pluripotent stem cells to promote cancer immunosurveillance.
|
Cancer Res
|
2011
|
0.98
|
|
36
|
Secondary infections, expanded tissue tropism, and evidence for malignant potential in immunocompromised mice infected with Mus musculus papillomavirus 1 DNA and virus.
|
J Virol
|
2013
|
0.96
|
|
37
|
Differences in N-linked glycosylation between human surfactant protein-B variants of the C or T allele at the single-nucleotide polymorphism at position 1580: implications for disease.
|
Biochem J
|
2003
|
0.95
|
|
38
|
Heparin-based ELISA reduces background reactivity in virus-like particle-based papillomavirus serology.
|
J Gen Virol
|
2005
|
0.94
|
|
39
|
Protective cell-mediated immunity by DNA vaccination against Papillomavirus L1 capsid protein in the Cottontail Rabbit Papillomavirus model.
|
Viral Immunol
|
2006
|
0.92
|
|
40
|
Differentiation-dependent interpentameric disulfide bond stabilizes native human papillomavirus type 16.
|
PLoS One
|
2011
|
0.90
|
|
41
|
GS-9191 is a novel topical prodrug of the nucleotide analog 9-(2-phosphonylmethoxyethyl)guanine with antiproliferative activity and possible utility in the treatment of human papillomavirus lesions.
|
Antimicrob Agents Chemother
|
2009
|
0.89
|
|
42
|
Mapping of human serum-reactive epitopes in virus-like particles of human papillomavirus types 16 and 11.
|
Virology
|
2003
|
0.89
|
|
43
|
Binding and neutralization characteristics of a panel of monoclonal antibodies to human papillomavirus 58.
|
J Gen Virol
|
2010
|
0.89
|
|
44
|
Characterization of immune responses during regression of rabbit oral papillomavirus infections.
|
Comp Med
|
2005
|
0.88
|
|
45
|
CRPV genomes with synonymous codon optimizations in the CRPV E7 gene show phenotypic differences in growth and altered immunity upon E7 vaccination.
|
PLoS One
|
2008
|
0.88
|
|
46
|
Maintaining GFP tissue fluorescence through bone decalcification and long-term storage.
|
Biotechniques
|
2002
|
0.88
|
|
47
|
Protein- and DNA-based active immunotherapy targeting interleukin-13 receptor alpha2.
|
Cancer Biother Radiopharm
|
2008
|
0.87
|
|
48
|
Identification of species-specific and cross-reactive epitopes in human polyomavirus capsids using monoclonal antibodies.
|
J Gen Virol
|
2009
|
0.87
|
|
49
|
Establishment of a cottontail rabbit papillomavirus/HLA-A2.1 transgenic rabbit model.
|
J Virol
|
2007
|
0.86
|
|
50
|
Human papillomavirus type 6 virus-like particles present overlapping yet distinct conformational epitopes.
|
J Gen Virol
|
2003
|
0.85
|
|
51
|
Multivalent human papillomavirus l1 DNA vaccination utilizing electroporation.
|
PLoS One
|
2013
|
0.84
|
|
52
|
Protective immunity with an E1 multivalent epitope DNA vaccine against cottontail rabbit papillomavirus (CRPV) infection in an HLA-A2.1 transgenic rabbit model.
|
Vaccine
|
2007
|
0.83
|
|
53
|
Detection of L1, infectious virions and anti-L1 antibody in domestic rabbits infected with cottontail rabbit papillomavirus.
|
J Gen Virol
|
2007
|
0.83
|
|
54
|
Differential binding patterns to host cells associated with particles of several human alphapapillomavirus types.
|
J Gen Virol
|
2009
|
0.82
|
|
55
|
Antibodies to human papillomavirus 16 L1 virus-like particles as an independent prognostic marker in cervical cancer.
|
Am J Obstet Gynecol
|
2002
|
0.82
|
|
56
|
Characterization of three rabbit oral papillomavirus oncogenes.
|
Virology
|
2004
|
0.81
|
|
57
|
Papillomavirus capsid proteins mutually impact structure.
|
Virology
|
2011
|
0.81
|
|
58
|
Expression of HPV-11 L1 protein in transgenic Arabidopsis thaliana and Nicotiana tabacum.
|
BMC Biotechnol
|
2007
|
0.81
|
|
59
|
Gene gun-mediated intracutaneous vaccination with papillomavirus E7 gene delays cancer development of papillomavirus-induced skin papillomas on rabbits.
|
Cancer Detect Prev
|
2002
|
0.80
|
|
60
|
The type 1 diabetes resistance locus B10 Idd9.3 mediates impaired B-cell lymphopoiesis and implicates microRNA-34a in diabetes protection.
|
Eur J Immunol
|
2014
|
0.80
|
|
61
|
Synonymous codon changes in the oncogenes of the cottontail rabbit papillomavirus lead to increased oncogenicity and immunogenicity of the virus.
|
Virology
|
2013
|
0.80
|
|
62
|
Human alpha and beta papillomaviruses use different synonymous codon profiles.
|
Virus Genes
|
2010
|
0.79
|
|
63
|
The innate immune adaptor MyD88 is dispensable for spontaneous autoimmune demyelination in a mouse model of multiple sclerosis.
|
J Neuroimmunol
|
2012
|
0.79
|
|
64
|
Mucosally-derived HPV-40 can infect both human genital foreskin and cutaneous hand skin tissues grafted into athymic mice.
|
Virus Res
|
2003
|
0.79
|
|
65
|
Using HLA-A2.1 Transgenic Rabbit Model to Screen and Characterize New HLA-A2.1 Restricted Epitope DNA Vaccines.
|
J Vaccines Vaccin
|
2010
|
0.78
|
|
66
|
Specific serologic response to genital human papillomavirus types in patients with vulvar precancerous and cancerous lesions.
|
Am J Obstet Gynecol
|
2005
|
0.78
|
|
67
|
Papillomavirus DNA complementation in vivo.
|
Virus Res
|
2009
|
0.78
|
|
68
|
Tracking vaginal, anal and oral infection in a mouse papillomavirus infection model.
|
J Gen Virol
|
2015
|
0.77
|
|
69
|
GM-CSF enhances protective immunity to cottontail rabbit papillomavirus E8 genetic vaccination in rabbits.
|
Vaccine
|
2004
|
0.77
|
|
70
|
Human Papillomavirus Vaccination Among Adults and Children in 5 US States.
|
J Public Health Manag Pract
|
2016
|
0.77
|
|
71
|
HPV binding assay to Laminin-332/integrin α6β4 on human keratinocytes.
|
Methods Mol Biol
|
2015
|
0.77
|
|
72
|
Protection from tumor recurrence following adoptive immunotherapy varies with host conditioning regimen despite initial regression of autochthonous murine brain tumors.
|
Cancer Immunol Immunother
|
2014
|
0.76
|
|
73
|
Differences in methodology, but not differences in viral strain, account for variable experimental outcomes in laboratories utilizing the cottontail rabbit papillomavirus model.
|
J Virol Methods
|
2009
|
0.76
|
|
74
|
Human papillomavirus type 18 chimeras containing the L2/L1 capsid genes from evolutionarily diverse papillomavirus types generate infectious virus.
|
Virus Res
|
2011
|
0.76
|
|
75
|
Increased immunity to cottontail rabbit papillomavirus infection in EIII/JC inbred rabbits after vaccination with a mutant E6 that correlates with spontaneous regression.
|
Viral Immunol
|
2007
|
0.76
|
|
76
|
Vaccine generated immunity targets an HPV16 E7 HLA-A2.1-restricted CD8(+) T cell epitope relocated to an early gene or a late gene of the cottontail rabbit papillomavirus (CRPV) genome in HLA-A2.1 transgenic rabbits.
|
Vaccine
|
2010
|
0.75
|
|
77
|
High incidence of spontaneous cataracts in aging laboratory rabbits of an inbred strain.
|
Vet Ophthalmol
|
2014
|
0.75
|
|
78
|
Pathogenesis of infection by human papillomavirus.
|
Curr Probl Dermatol
|
2014
|
0.75
|